Want to see HK:1167 full AI Analyst Report?
Top Page
Jacobio Pharmaceuticals Group Co., Ltd.
(1167)
Select Model
Select Model
Rating:52Neutral
Price Target:
HK$4.50
▼(-44.17% Downside)
Action:Reiterated
Date:08/26/26
Overall score is held back primarily by weak financial performance—sharp revenue decline, ongoing losses, and sustained negative free cash flow implying continued funding sensitivity. Technicals provide a modest offset with improving near-term trend and neutral-to-positive momentum, while valuation is supportive on a low P/E but lacks dividend yield support.
Positive Factors
Manageable Leverage
Relatively low debt compared with equity gives Jacobio greater balance-sheet flexibility than a heavily leveraged biotech. This can preserve room to fund clinical development, absorb operating volatility, and pursue strategic opportunities, although the benefit is tempered by declining equity and continuing losses.
Negative Factors
Sharp Revenue Contraction
A revenue decline of this magnitude weakens visibility into the company’s ability to generate recurring income and indicates that recent revenue performance is highly volatile. For a clinical-stage biotech, reduced income can make development spending more dependent on partnerships, milestones, or external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
Relatively low debt compared with equity gives Jacobio greater balance-sheet flexibility than a heavily leveraged biotech. This can preserve room to fund clinical development, absorb operating volatility, and pursue strategic opportunities, although the benefit is tempered by declining equity and continuing losses.
Read all positive factors
Jacobio Pharmaceuticals Group Co., Ltd. (1167) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.62B
Dividend YieldN/A
Average Volume (3M)1.06M
Price to Earnings (P/E)6.0
Beta (1Y)0.74
Revenue Growth286.20%
EPS GrowthN/A
CountryHK
Employees207
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.65
Shares Outstanding791,755,070
10 Day Avg. Volume672,834
30 Day Avg. Volume1,055,024
Financial Highlights & Ratios
PEG Ratio3.18
Price to Book (P/B)5.75
Price to Sales (P/S)84.99
P/FCF Ratio-23.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.34Price Target Upside28.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.63
Revenue Forecast (FY)HK$766.33M
Jacobio Pharmaceuticals Group Co., Ltd. Business Overview & Revenue Model
Company Description
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src hom...
How the Company Makes Money
Jacobio’s revenue model is primarily based on monetizing its drug discovery and development capabilities and the value of its clinical pipeline. Key revenue streams typically include: (1) collaboration and licensing income, where the company may o...
Jacobio Pharmaceuticals Group Co., Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
62
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 728.51M | 52.14M | 155.71M | 63.52M | 95.75M | 152.81M |
| Gross Profit | 687.70M | 29.35M | 155.71M | 3.20M | 12.63M | 12.83M |
| EBITDA | 513.83M | -142.87M | -176.73M | -325.73M | -355.80M | -289.83M |
| Net Income | 506.80M | -142.20M | -155.71M | -359.12M | -371.86M | -301.19M |
Balance Sheet | ||||||
| Total Assets | 1.86B | 1.30B | 1.36B | 1.46B | 1.57B | 1.72B |
| Cash, Cash Equivalents and Short-Term Investments | 1.68B | 1.10B | 1.17B | 1.15B | 1.28B | 1.54B |
| Total Debt | 159.78M | 165.24M | 152.08M | 209.91M | 147.79M | 6.81M |
| Total Liabilities | 511.70M | 533.92M | 435.99M | 387.11M | 292.12M | 84.75M |
| Stockholders Equity | 1.35B | 770.96M | 923.18M | 1.07B | 1.28B | 1.64B |
Cash Flow | ||||||
| Free Cash Flow | 544.99M | -187.27M | -86.21M | -402.86M | -308.92M | -158.63M |
| Operating Cash Flow | 546.02M | -186.20M | -74.12M | -364.20M | -292.42M | -147.49M |
| Investing Cash Flow | -832.29M | -138.63M | 256.22M | -48.00M | -686.32M | 161.67M |
| Financing Cash Flow | -15.60M | 45.20M | 21.28M | 246.28M | -9.85M | 109.06M |
Jacobio Pharmaceuticals Group Co., Ltd. Technical Analysis
Negative
8.06
Price Trends
5.70
Negative
5.27
Negative
5.84
Negative
Market Momentum
-0.30
Positive
31.56
Neutral
8.06
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1167, the sentiment is Negative. The current price of 8.06 is above the 20-day moving average (MA) of 5.31, above the 50-day MA of 5.70, and above the 200-day MA of 5.84, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 31.56 is Neutral, neither overbought nor oversold. The STOCH value of 8.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1167.
Jacobio Pharmaceuticals Group Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | HK$3.26B | 4.48 | 10.99% | ― | 1417.68% | 660.14% | |
52 Neutral | HK$3.62B | 6.01 | 47.76% | ― | 286.20% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$10.12B | -5.93 | -153.78% | ― | 70.26% | -12.79% | |
47 Neutral | HK$6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% | |
44 Neutral | HK$1.80B | 29.59 | 6.51% | ― | 605.95% | ― | |
41 Neutral | HK$7.77B | -15.53 | -43.54% | ― | 116.67% | -0.42% |
* Healthcare Sector Average
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
4.60
-2.66
-36.64%
HK:6996
Antengene Corporation Limited
2.79
-2.33
-45.51%
HK:6998
Genor Biopharma Holdings Limited
1.62
-1.51
-48.24%
HK:9966
Alphamab Oncology
6.22
-5.47
-46.79%
HK:2616
CStone Pharmaceuticals
4.94
-1.28
-20.58%
HK:6855
Ascentage Pharma Group International
27.20
-40.70
-59.94%
Jacobio Pharmaceuticals Group Co., Ltd. Corporate Events
Jacobio Advances KRAS Oncology Pipeline as Glecirasib Gains Traction in China
Aug 24, 2026
Jacobio Pharmaceuticals reported interim results marked by continued progress in its oncology pipeline, led by glecirasib and sitneprotafib for KRAS G12C-mutated cancers. Glecirasib monotherapy has secured Chinese approval for second-line NSCLC, e...
Jacobio Pharmaceuticals Sets Board Meeting to Approve Interim 2026 Results
Aug 12, 2026
Jacobio Pharmaceuticals has scheduled a board meeting for August 24, 2026 to review and approve its interim financial results for the six months ended June 30, 2026. The board will also consider publication of these results and address any other c...
Jacobio Pharmaceuticals Forecasts First Interim Profit on Licensing-Driven Revenue Surge
Aug 10, 2026
Jacobio Pharmaceuticals reported that it expects to achieve its first-ever net profit of at least RMB600 million for the six months ended June 30, 2026, reversing a net loss of about RMB59 million a year earlier. The turnaround is driven by strong...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.